A Novel Immune-Related ceRNA Network and Relative Potential Therapeutic Drug Prediction in ccRCC

Weiquan Li; Weiquan Li; Weiquan Li; Xiangui Meng; Xiangui Meng; Xiangui Meng; Hongwei Yuan; Hongwei Yuan; Hongwei Yuan; Wen Xiao; Wen Xiao; Wen Xiao; Xiaoping Zhang; Xiaoping Zhang; Xiaoping Zhang

doi:10.3389/fgene.2021.755706

Frontiers in Genetics (Jan 2022)

A Novel Immune-Related ceRNA Network and Relative Potential Therapeutic Drug Prediction in ccRCC

Weiquan Li,
Weiquan Li,
Weiquan Li,
Xiangui Meng,
Xiangui Meng,
Xiangui Meng,
Hongwei Yuan,
Hongwei Yuan,
Hongwei Yuan,
Wen Xiao,
Wen Xiao,
Wen Xiao,
Xiaoping Zhang,
Xiaoping Zhang,
Xiaoping Zhang

Affiliations

Weiquan Li: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Weiquan Li: Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, China
Weiquan Li: Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Xiangui Meng: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Xiangui Meng: Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, China
Xiangui Meng: Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Hongwei Yuan: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Hongwei Yuan: Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, China
Hongwei Yuan: Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Wen Xiao: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Wen Xiao: Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, China
Wen Xiao: Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Xiaoping Zhang: Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
Xiaoping Zhang: Shenzhen Huazhong University of Science and Technology Research Institute, Shenzhen, China
Xiaoping Zhang: Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

DOI: https://doi.org/10.3389/fgene.2021.755706
Journal volume & issue: Vol. 12

Abstract

Read online

Renal cell carcinoma (RCC) is the third common solid tumor in the urinary system with a high distant metastasis rate. The five-year survival rate of RCC has reached 75%, benefiting from the emergence and update of multiple treatments, while its pathogenesis and prognostic markers are still unclear. In this study, we committed to explore a prognostic ceRNA network that could participate in the development of RCC and had not been studied yet. We screened nine immune-related hub genes (AGER, HAMP, LAT, LTB4R, NR3C2, SEMA3D, SEMA3G, SLC11A1, and VAV3) using data of The Cancer Genome Atlas Kidney Clear Cell Carcinoma database (TCGA-KIRC) through survival analysis and the cox proportional hazard model. Next, we successfully constructed a ceRNA network of two mRNA (NR3C2 and VAV3), miRNA (hsa-miR-186-5p), and lncRNA (NNT-AS1) for ccRCC based on numerous online bioinformatics tools and Cytoscape. Finally, we predicted five potential drugs (clemizole, pentolonium, dioxybenzone, Prestwick-691, and metoprolol) based on the above results.

Published in Frontiers in Genetics

ISSN: 1664-8021 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Biology (General): Genetics
Website: http://journal.frontiersin.org/journal/genetics

About the journal

Abstract

Keywords